China Medical System Holdings (2M7C) Stock Overview
An investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
2M7C Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
China Medical System Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.56 |
| 52 Week High | HK$1.65 |
| 52 Week Low | HK$0.81 |
| Beta | 1.3 |
| 1 Month Change | 6.12% |
| 3 Month Change | 1.30% |
| 1 Year Change | 71.43% |
| 3 Year Change | 1.30% |
| 5 Year Change | 9.09% |
| Change since IPO | 449.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2M7C | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 6.8% | -4.5% | 0.7% |
| 1Y | 71.4% | 16.6% | 6.7% |
Return vs Industry: 2M7C exceeded the German Pharmaceuticals industry which returned 18.7% over the past year.
Return vs Market: 2M7C exceeded the German Market which returned 8.7% over the past year.
Price Volatility
| 2M7C volatility | |
|---|---|
| 2M7C Average Weekly Movement | 5.0% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 13.2% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 2M7C has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 2M7C's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 6,095 | Kong Lam | web.cms.net.cn/zh/home/ |
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. The company offers cardio-cerebrovascular products include VELPHORO, a sucroferric oxyhydroxide chewable tablets and diazepam nasal spray for seizure clusters; XinHuoSu, a recombinant human brain natriuretic peptide for acute heart failure; Plendil, a felodipine sustained release tablets for hypertension; and Deanxit, a flupentixol and melitracen tablets for mild-to-moderate depression. It also provides gastroenterology products, such as METOJECT, a methotrexate injection to treat severe recalcitrant disabling psoriasis and rheumatoid arthritis; LUMEBLUE, a methylthioninium chloride enteric-coated sustained-release tablets for colorectal lesion visualization; Salofalk for ulcerative colitis and Crohn’s disease; Bioflor, a saccharomyces boulardii sachets for diarrhea; Combizym and Cidine for digestive enzymes; and Ursofalk, a ursodeoxycholic acid capsules to treat cholesterol gallstones.
China Medical System Holdings Limited Fundamentals Summary
| 2M7C fundamental statistics | |
|---|---|
| Market cap | €3.90b |
| Earnings (TTM) | €201.92m |
| Revenue (TTM) | €961.54m |
Is 2M7C overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2M7C income statement (TTM) | |
|---|---|
| Revenue | CN¥7.86b |
| Cost of Revenue | CN¥2.24b |
| Gross Profit | CN¥5.62b |
| Other Expenses | CN¥3.97b |
| Earnings | CN¥1.65b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.68 |
| Gross Margin | 71.47% |
| Net Profit Margin | 21.00% |
| Debt/Equity Ratio | 4.2% |
How did 2M7C perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/05 23:25 |
| End of Day Share Price | 2026/02/05 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
China Medical System Holdings Limited is covered by 30 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jessica Li | BofA Global Research |
| Lok Kwan Chiu | CCB International Securities Limited |
| Harry He | China Galaxy International Securities (Hong Kong) |